Neoadjuvant Chemoimmunotherapy Deemed Safe, Effective in Esophageal Cancer
Neoadjuvant chemotherapy combined with an immune checkpoint inhibitor is safe and effective in patients with resectable esophageal cancer, a real-world study suggests.
Diagnosis & Disease Information
Surgical Resection Improves Survival but Remains Underused in LS-SCLC
Patients with LS-SCLC have better survival outcomes at 1 year and 5 years if they undergo surgical resection, a large study suggests.
SGLT2 Expression in Lung Cancer Differs by Sex, Histology, and Tumor Grade
An analysis of lung cancer specimens revealed the strongest SGLT2 expression in carcinoid tumors, adenosquamous carcinomas, and adenocarcinomas.
Results of a Multidisciplinary Treatment Approach for Superior Sulcus NSCLC
A multidisciplinary treatment approach can produce favorable outcomes in patients with superior sulcus NSCLC, according to researchers.
Positive Station 9 Lymph Nodes Associated With Middle and Lower Lobe NSCLC
Station 9 lymph nodes should be sampled for primary non-small cell lung cancer of the middle and lower lobes, according to researchers.
COVID-19 May Triple the Risk of Death During NSCLC Treatment
Patients with non-small cell lung cancer may have a 3-fold higher risk of death if they develop COVID-19, a study suggests.
Salvage Resection After Immunotherapy May Be Beneficial in NSCLC
Salvage resection may benefit patients with NSCLC who have residual or recurrent disease after immunotherapy, a study suggests.
Alectinib, Crizotinib Induction Deemed Feasible in Stage III, ALK+ NSCLC
Induction with alectinib or crizotinib is clinically feasible in ALK-positive, stage III non-small cell lung cancer, according to researchers.
Disparities in Clinical Trial Enrollment Among NSCLC Patients
Several groups of patients are underrepresented in NSCLC clinical trials, new research suggests.
Levels of Air Pollutants Tied to Incidence of Lung Cancer
Reductions in air pollutants coincided with reductions in lung cancer incidence in a Michigan county, researchers found.
- Loading...
Loading...
Next post in AATS 2023
Loading... 
Loading...